Diphenylformamide (DPF) is a versatile organic compound used in various fields, including pharmaceuticals, polymers, and dyes. It is typically synthesized through the reaction of formic acid with diphenylamine in the presence of a catalyst. DPF exhibits antibacterial activity and has been investigated for its potential as a therapeutic agent against bacterial infections. Its unique chemical structure allows for its use as a monomer in the synthesis of polymers with interesting properties. Moreover, DPF is employed in the production of dyes and pigments, contributing to the coloration of various materials. The study of DPF is driven by its multifaceted applications and its potential to contribute to advancements in medicine, materials science, and other fields.'
| ID Source | ID |
|---|---|
| PubMed CID | 69081 |
| SCHEMBL ID | 43388 |
| MeSH ID | M0067891 |
| Synonym |
|---|
| HMS1577L14 |
| nsc-3864 |
| formamide,n-diphenyl- |
| diphenylformamide |
| nsc3864 |
| 607-00-1 |
| n,n-diphenylformamide |
| formanilide, n-phenyl- |
| formamide, n,n-diphenyl- |
| STK298772 |
| n,n-diphenylformamide, 99% |
| 1NO9 |
| AK-968/13465018 |
| ai3-01800 |
| nsc 3864 |
| einecs 210-129-6 |
| formyldiphenylamine |
| D0890 |
| inchi=1/c13h11no/c15-11-14(12-7-3-1-4-8-12)13-9-5-2-6-10-13/h1-11h |
| dcnuqrblzwsgav-uhfffaoysa- |
| AKOS003792096 |
| ff0x003442 , |
| unii-ff0x003442 |
| FT-0632525 |
| SCHEMBL43388 |
| n-phenylformanilide |
| n-formyldiphenylamine |
| DTXSID9022077 |
| mfcd00003282 |
| CCG-308586 |
| D70356 |
| Q27277952 |
| n.n-diphenylformamide |
| SY051553 |
| AS-57483 |
| CS-0156141 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain H, Alpha Thrombin | Homo sapiens (human) | Ki | 0.0240 | 0.0240 | 0.0240 | 0.0240 | AID977610 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1811 | Experimentally measured binding affinity data derived from PDB | 2003 | Biochemistry, Aug-05, Volume: 42, Issue:30 | Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies. |
| AID977610 | Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB | 2003 | Biochemistry, Aug-05, Volume: 42, Issue:30 | Design of weakly basic thrombin inhibitors incorporating novel P1 binding functions: molecular and X-ray crystallographic studies. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.52) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||